BSE: 524400
ISHITA DRUGS & INDUSTRIES LTD.
Manufactures pharmaceutical products at an Indian facility, generating Rs 14.66 crore of revenue in FY26. Raw materials make up 69.2% of revenue — the dominant cost — followed by employee costs at 9.4% and other operating expenses at 15.0%. The company is upgrading its manufacturing facility to comply with India's Revised Schedule M norms; as of December 2025, the new warehouse block was nearly complete and Rs 1.75 crore of capital work-in-progress sat on the balance sheet at year-end. It held Rs 12.60 crore of total assets, earned Rs 0.78 crore of net profit, and ran an 8.45% EBITDA margin in FY26. The filings do not break out revenue by product category or therapeutic segment, and the customer mix is not disclosed. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Pharmaceutical manufacturing (100%). Small, single-facility pharmaceutical manufacturer; materials-intensive, currently capex-heavy on regulatory upgradation
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 14 | 12 | 15 | 15 | 15 |
| EBITDA (ex other income) | 1 | 1 | 1 | 1 | 1 |
| margin % | 7.7 | 6.3 | 6.0 | 6.7 | 5.2 |
| Owners' profit | 1 | 1 | 1 | 1 | 1 |
| EPS, as reported (₹) | 2.69 | 1.93 | 2.50 | 2.90 | 2.60 |
| ROE % · ROCE % | 9.4 · 12.4 | 6.3 · 9.1 | 7.5 · 10.8 | 8.0 · 11.3 | 6.7 · 9.8 |
| Debt / equity (x) | 0.00 | 0.10 | 0.00 | 0.36 | 0.01 |
| Cash from operations | 3 | (3) | 2 | (4) | 4 |
| Capex | 0 | 0 | 0 | 0 | (2) |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 3 | 4 | 5 | 5 | 3 | 3 | 3 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (₹) | 0.49 | 0.65 | 0.80 | 0.96 | 1.01 | 0.48 | 0.52 | 0.59 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,21,677 | 34.9 | 5.03 | 22.6 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,53,976 | 87.0 | 15.15 | 65.5 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,54,957 | 73.1 | 8.81 | 38.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| LAURUS LABS LIMITED | 1,17,877 | 107.7 | 21.70 | 65.6 | 16.4 | 17.2 | 7.2 | 32.0 |
| ZYDUS LIFESCIENCES LTD | 1,17,315 | 26.2 | 3.97 | 15.1 | 17.3 | 18.0 | 12.4 | 25.2 |
| DR. REDDY S LABORATORIES | 1,11,506 | 34.5 | 2.92 | 14.9 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,10,320 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,02,829 | 50.3 | 6.21 | 28.3 | 11.7 | 10.8 | — | 27.3 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 28.7 | 30.8 | 77 of 158 | 52% |
| P/B | 1.9 | 3.1 | 52 of 163 | 69% |
| ROCE | 9.3 | 10.8 | 104 of 183 | 43% |
| ROE | 6.7 | 9.8 | 108 of 166 | 35% |
| Debt / Equity | 0.0 | 0.2 | 43 of 166 | 75% |
| EBITDA margin | 10.2 | 17.5 | 120 of 165 | 27% |
| Revenue growth | (33.0) | 16.3 | 150 of 161 | 7% |
| Profit growth | (38.4) | 30.9 | 125 of 158 | 21% |
| Market cap | 22 | 806 | 163 of 181 | 10% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 28 Oct 2026 · Board to approve September 2026 quarterly results | results | low | — | — |
| 13 Oct 2026 · Routine SEBI compliance certificate filed for Q2 FY26 | compliance | minimal | — | — |
| 2 Oct 2026 · Re-appointment of Director and Statutory Auditor approved at AGM | management changes | medium | — | — |
| 2 Oct 2026 · Re-appointment of Statutory Auditor Jaymin Shah & Associates for FY 2026-27 | management changes | medium | — | — |
| 2 Oct 2026 · Ishita Drugs 33rd AGM: All 5 resolutions passed | board shareholder meetings | low | — | — |
| 30 Sept 2026 · 33rd AGM held; key resolutions approved | board shareholder meetings | low | — | — |
| 26 Sept 2026 · Trading window closed from Oct 1 ahead of Q2 results | compliance | minimal | — | — |
| 22 Sept 2026 · Ishita Drugs avails 11.75 Cr loan from HDFC Bank for facility upgrade | credit debt | medium | — | — |
| 22 Sept 2026 · Board approves about 11.75 crore borrowings from HDFC Bank | credit debt | medium | — | — |
| 18 Sept 2026 · Board to consider raising funds via working capital and term loans | fund raising | medium | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.